Intravascular Lithotripsy Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The intravascular lithotripsy devices market size is expected to increase from USD 1.15 billion in 2025 to USD 1.33 billion in 2026 and reach USD 2.71 billion by 2031, growing at a CAGR of 15.35% over 2026-2031. This report is segmented by Product Type (Catheters and Balloons, Generators, Guidewires), Vessel Type (Coronary, Femoropopliteal, Iliac, Below-The-Knee, Other), Technology (Balloon-Based, Forward-Firing, IVUS-Guided, Hybrid IVL), End User (Hospitals, Cath Labs, Vascular Clinics, and More), and Geography (North America, Europe, Asia-Pacific, and More). Market Forecasts in Terms of Value (USD).

Global Intravascular Lithotripsy Devices Market Trends and Insights

Rising Burden of Severely Calcified Coronary and Peripheral Artery Disease

The intravascular lithotripsy devices market is supported by an increase in complex calcium burden, rather than cardiovascular disease incidence alone. The cited global burden study reported 239 million prevalent ischemic heart disease cases and 122 million lower-extremity PAD cases in 2023. Aging, hypertension, diabetes, and chronic kidney disease increase the severity of vascular calcification in these patient populations. The 2025 clinical study found calcified lesions in 25%-50% of CAD patients undergoing PCI and linked inadequate modification with vascular complications and worse long-term outcomes. Standard balloons are less suitable when calcium arc and thickness prevent adequate lesion preparation. Quality frameworks in the United States and Europe also place greater attention on stent expansion, which supports more complete calcium preparation before implantation.

Increasing Complexity of Percutaneous Coronary Intervention

The intravascular lithotripsy devices market benefits as physicians manage more multivessel disease, left-main disease, and calcified chronic total occlusions. These anatomical settings can result in inadequate stent expansion when conventional balloon angioplasty is used alone. A seven-center European registry of 454 patients found that IVL use in acute coronary syndrome cases increased over time, with p=0.004. A separate 2025 study reported intravascular imaging use in 94.3% of left-main IVL procedures, compared with 40.5% of non-left-main cases. These cases commonly combine IVL with IVUS, increasing the role of imaging and device planning within the procedure. The CT-IVL score achieved an AUC of 0.81 for predicting IVL need in the cited study, which can support more objective patient selection before entry to the catheterization laboratory.

High Single-Use Catheter Cost and Uneven Reimbursement Access

Single-use catheter pricing constrains the intravascular lithotripsy devices market, especially in systems without a dedicated payment route. Coronary IVL catheters carry list prices of USD 2,250-USD 4,750 per unit, while peripheral catheters reach USD 4,900 per unit. Multiple catheters can be required for complex lesions, which increases the cost of each procedure. Hospitals receiving global procedure payments may recognize the clinical benefit but lack a matching route to recover the device cost. This issue is more acute in emerging markets and can limit adoption to private networks with fee-for-service billing. Generator-free and simplified systems from Elixir Medical and FastWave Medical aim to reduce capital or per-procedure costs, although their reach remains investigational or limited in 2026.

Other drivers and restraints analyzed in the detailed report include:

• Growing Clinical Evidence for Predictable Calcium Modification
• Improving Reimbursement for Coronary Intravascular Lithotripsy
• Limited Comparative Evidence and Lesion-Access Constraints

Segment Analysis

IVL Catheters and Balloons held 56.31% of the intravascular lithotripsy devices market share in 2025. This position in the intravascular lithotripsy devices market reflected the consumable role of catheter technology in each procedure and Shockwave Medical’s established catheter portfolio. Guidewires and Accessories remained the smallest product group. They benefit from below-the-knee treatment because distal tibial delivery requires hydrophilic-coated guidewires with strong pushability. Generators and Console Systems are projected to grow at a CAGR of 17.65% from 2026 to 2031. The intravascular lithotripsy devices market size for generator platforms is supported by new systems that require compatible consoles.

Generator growth continues despite the emergence of generator-free platforms such as Elixir LithiX HC-IVL. Boston Scientific Bolt, Abbott Coronary IVL, and Stryker AVS Pulse IVL each require facilities to consider compatible generator equipment. New regulatory clearances can therefore expand capital deployment before catheter procedure volumes increase. A 2025 study reported that IVUS-guided IVL independently achieved superior stent expansion compared with angiography-guided procedures. This relationship supports demand for imaging and accessory products alongside IVL. FastWave’s laser-based Sola system may change the cost structure if its feasibility findings are replicated at a commercial scale, but it remained an early-stage alternative in 2026.

Coronary vessels commanded 57.24% of revenue in 2025. This position in the intravascular lithotripsy devices market was built on Shockwave’s C2 and C2 Plus catheters and the Disrupt CAD clinical series across several coronary calcium presentations. The C2 Aero catheter received an instructions-for-use document in July 2025, adding a lower-profile iteration to the portfolio. Below-the-Knee Arteries are projected to expand at a CAGR of 18.22% from 2026 to 2031. The 30-day Disrupt PAD BTK II study reported 97.9% procedural success in 250 patients with mainly moderate-to-severe calcification.

One-year BTK II results presented in 2025 reported sustained safety and efficacy in a cohort that included 80% chronic limb-threatening ischemia and 70% diabetes. The results also reported low clinically driven target lesion revascularization rates and symptomatic improvement. These patient characteristics align with the growing prevalence of complex peripheral disease. Femoropopliteal and iliac procedures contribute meaningful revenue because 2025 reimbursement codes cover IVL across these vascular territories. The FORWARD PAD studies reported 99% technical success for the Javelin catheter. The forward-firing design reduces dependence on a pre-crossable stenosis, which broadens the procedures that can be considered for peripheral IVL.

Complete Report Scope:

• By Product Type
  • Intravascular Lithotripsy Catheters and Balloons
  • Generators and Console Systems
  • Guidewires and Accessories
• By Vessel Type
  • Coronary Arteries
  • Femoropopliteal Arteries
  • Iliac Arteries
  • Below-the-Knee Arteries
  • Other Vessel Types
• By Technology
  • Balloon-Based IVL
  • Forward-Firing IVL
  • Intravascular Ultrasound (IVUS)-Guided IVL
  • Hybrid / Next-Generation IVL Systems
• By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Cardiac Catheterization Laboratories
  • Specialty Vascular Clinics
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 56.61% of the intravascular lithotripsy devices market share in 2025. The United States remains the main source of first-generation IVL clearances and the largest procedural volume country. Fiscal year 2025 MS-DRGs supplied USD 10,000 in incremental payment above standard PCI with a stent. Calendar year 2026 physician reimbursement includes USD 122 for the CPT add-on code +92972. These payments reduce the financial barrier for academic centers and regional hospital networks.

Canada and Mexico lag the United States in reimbursement maturity and device access, which limits the region’s share expansion. Europe remains the second-largest regional contributor to the intravascular lithotripsy devices market. Germany, the United Kingdom, France, Italy, and Spain account for most regional coronary and peripheral volume. The 454-patient European registry reported 98% device success and increasing IVL use with imaging and acute coronary syndrome treatment. Germany’s DRG structure accommodates reimbursement, while NICE IPG780 provides an evidence-review reference for peripheral calcification decisions in the United Kingdom.

Asia-Pacific is projected to grow at a CAGR of 18.65% from 2026 to 2031. Aging populations, calcified coronary disease, regulatory activity in China, and expanding cardiology capacity support the intravascular lithotripsy devices market size in the region. At least 5 domestically manufactured IVL systems had received NMPA approval in China by 2024, including MicroPort RotaPace’s TomaHawk system. Domestic competition can lower unit prices and extend access beyond leading hospitals. MicroPort’s intravascular piezoelectric guidewire system entered China’s Green Path review in June 2024, indicating work on guidewire-integrated designs. Japan and South Korea have established insurance coverage for coronary intervention, while Australian activity remains concentrated in metropolitan academic hospitals. The Middle East and Africa, and South America, remain smaller contributors, with adoption concentrated in private and academic centers and constrained by uneven reimbursement, currency volatility, and limited catheterization laboratory density.

List of Companies Covered in this Report:

• Abbott Laboratories
• Avinger, Inc.
• AVS Pulse, Inc.
• B. Braun
• BIOTRONIK
• Boston Scientific
• Cagent Vascular, LLC
• Cook Group
• Elixir Medical
• FastWave Medical, Inc.
• Johnson & Johnson
• Koninklijke Philips
• Medtronic
• MicroPort
• Spectrumedics Medical
• Stryker
• Teleflex
• Terumo

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support